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Abstract
Safranal, contained in Crocus sativus L., exerts anti‐inflammatory and analgesic
effects. However, the underlying mechanisms for such effects are poorly under-
stood. We explored whether safranal targets the transient receptor potential ankyrin
1 (TRPA1) channel, which in nociceptors mediates pain signals. Safranal by binding
to specific cysteine/lysine residues, stimulates TRPA1, but not the TRP vanilloid 1
and 4 channels (TRPV1 and TRPV4), evoking calcium responses and currents in
human cells and rat and mouse dorsal root ganglion (DRG) neurons. Genetic deletion
or pharmacological blockade of TRPA1 attenuated safranal‐evoked release of calci-
tonin gene‐related peptide (CGRP) from rat and mouse dorsal spinal cord, and acute
nociception in mice. Safranal contracted rat urinary bladder isolated strips in a
TRPA1‐dependent manner, behaving as a partial agonist. After exposure to safranal
the ability of allyl isothiocyanate (TRPA1 agonist), but not that of capsaicin (TRPV1
agonist) or GSK1016790A (TRPV4 agonist), to evoke currents in DRG neurons, con-
traction of urinary bladder strips and CGRP release from spinal cord slices in rats,
and acute nociception in mice underwent desensitization. As previously shown for
other herbal extracts, including petasites or parthenolide, safranal might exert
analgesic properties by partial agonism and selective desensitization of the TRPA1
channel.
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1 | INTRODUCTION
Crocus sativus L., known as saffron crocus, belongs to the family of
Iridaceas1 and is commonly used for flavouring and colouring food
preparations. Saffron extracts contain three main bioactive
constituents: the carotenoid crocin, responsible for its typical col-
our, the monoterpene aldehyde picrocrocin, and the volatile com-
pound safranal, which accounts for its special flavour.2 Saffron has
been reported to possess beneficial effects against depression, sex-
ual dysfunction, premenstrual syndrome and weight loss.1,3
Although clinical trials reported headache as one possible adverse
effect of saffron,4 in Indian traditional medicine saffron has beenLi Puma and Landini are Equally contributing authors.
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used to treat headache.5 Preclinical studies focused on the pharma-
cological activity of saffron and its purified constituents, suggesting
anti‐oxidant,6 anti‐inflammatory7 and antinociceptive8 properties of
the golden spice. Antinociceptive effect of safranal has been
demonstrated in models of inflammatory pain, such as formalin,
acetic acid or carrageenan,8 and in models of neuropathic pain,
including chronic constriction injury and nerve crush injury.9,10 The
analgesic action of safranal has been attributed to its ability to sup-
press glial activation and proinflammatory cytokines production in
the central nervous system.11 However, the underlying mechanisms
responsible for the analgesic action of saffron have not been yet
elucidated.
Transient receptor potential (TRP) channels are pleiotropic exci-
tatory ion channels present in a large variety of cells. Some TRPs are
highly expressed by specific subpopulations of primary sensory noci-
ceptive neurons, where they contribute to sensing noxious chemical,
mechanical and thermal stimuli.12–14 In particular, the TRP ankyrin 1
(TRPA1) is coexpressed with the vanilloid type 1 (TRPV1, the cap-
saicin receptor), or the vanilloid type 4 (TRPV4) by a subpopulation
of nociceptors, which contain and release the proinflammatory neu-
ropeptide calcitonin gene‐related peptide (CGRP) and substance P
(SP).12,13 CGRP and SP released from peripheral endings of primary
afferents mediate neurogenic inflammation13 and CGRP is now rec-
ognized to play an essential role in migraine pain.13,15 TRPA1 is acti-
vated by a number of exogenous irritant and pungent agents,
including allyl isothiocyanate (AITC), cinnamaldehyde16,17 and forma-
lin.18 Notably, reactive oxygen, nitrogen and carbon species gate
TRPA1 by reacting with specific cysteine/lysine residues, thus medi-
ating pain and neurogenic inflammation.19–23
Here, we evaluated whether the three main constituents of saf-
fron affect the function of TRP channels expressed in nociceptors,
and in particular that of TRPA1. We found that safranal and its pre-
cursor, picrocrocin, but not crocin, selectively activate TRPA1, but
not TRPV1 or TRPV4, safranal being far more effective than picro-
crocin. In addition, safranal behaves as a partial agonist on TRPA1 as
compared to the full agonist, AITC. Finally, safranal induces selective
desensitization of the TRPA1 channel, thus attenuating neuronal
excitation that results in nociception and CGRP release. This unfore-
seen TRPA1‐desensitization mechanism could possibly explain the
analgesic effects attributed to saffron.
2 | MATERIALS AND METHODS
2.1 | Animals
In vivo experiments and tissue collection were carried out according
to the European Union (EU) directive guidelines (2010/63/EU) and
Italian legislation (DLgs 26/2014) for animal care procedures. Studies
were conducted under the University of Florence research permit
#194/2015‐PR. Animals were housed in a temperature‐ and humid-
ity‐controlled vivarium (12‐hour dark/light cycle, free access to food
and water) and were allowed to acclimatize for at least 7 days prior
to experimentation. Animal studies were reported in compliance with
the ARRIVE guidelines.24,25 A group size of six animals for beha-
vioural experiments was determined by sample size estimation using
G*Power (v3.1)26 to detect size effect in a post‐hoc test with type 1
and 2 error rates of 5 and 20% respectively. Allocation concealment
was performed using a randomization procedure (http://www.rand
omizer.org/).
The following mouse strains were used: C57BL/6 mice (male, 20‐
25 g, 5 weeks; Envigo, Milan, Italy); littermate TRPA1 wild‐type
(Trpa1+/+) and TRPA1‐deficient (Trpa1−/−) mice (25‐30 g, 5‐8 weeks)
generated by heterozygotes on a C57BL/6 background (B6.129P‐
Trpa1tm1Kykw/J; Jackson Laboratories, Bar Harbor, ME, USA); wild‐
type (Trpv4+/+) and TRPV4‐deficient (Trpv4−/−) mice (25‐30 g, 5‐
8 weeks), generated by heterozygotes on a C57BL/6 background27
and TRPV1‐deficient mice (Trpv1−/−; B6.129X1‐Trpv1tm1Jul/J) back-
crossed with C57BL/6 mice (Trpv1+/+) for at least 10 generations
(Jackson Laboratories; 25‐30 g, 5‐8 weeks). Sprague‐Dawley rats
(male, 75‐100 g, Envigo) were also used. Animals were killed with
inhaled CO2 plus 10%‐50% O2.
2.2 | Cell culture
Naïve untransfected HEK293 cells (American Type Culture Collec-
tion, Manassas, VA, USA; ATCC® CRL‐1573™) were cultured accord-
ing to the manufacturer's instructions. HEK293 cells were transiently
transfected with the cDNAs (1 μg) codifying for wild‐type (wt‐
hTRPA1) or mutant 3C/K‐Q human TRPA1 (C619S, C639S, C663S,
K708Q; 3C/K‐Q hTRPA1‐HEK293)23 using the jetPRIME transfection
reagent (Poliyplus‐transfection® SA, Strasburg, France) following the
manufacturer's protocol. HEK293 cells stably transfected with cDNA
for human TRPA1 (hTRPA1‐HEK293), or with cDNA for human
TRPV1 (hTRPV1‐HEK293), or with cDNA for human TRPV4
(hTRPV4‐HEK293) were cultured as previously described.28 Human
foetal lung fibroblasts (IMR90; American Type Culture Collection;
ATCC® CCL‐186™), which express the native TRPA1 channel, were
cultured as previously described.29 Cells were plated on glass‐coated
(poly‐L‐lysine, 8.3 μmol/L) coverslips and cultured for 1‐2 days before
being used for recordings.
2.3 | Isolation of primary sensory neurons
Primary dorsal root ganglion (DRG) neurons were isolated from adult
Sprague‐Dawley rats and Trpa1+/+ and Trpa1−/− mice, and cultured
as previously described.30 Briefly, DRG were bilaterally excised and
transferred to Hank's Balanced Salt Solution containing trypsin
(1 mg/mL) and collagenase type 1A or papain (both, 2 mg/mL), for rat
or mouse ganglia respectively (35 minutes, 37°C). Ganglia were then
transferred to warm Dulbecco's Modified Eagle Medium supple-
mented with 10% foetal bovine serum, 10% horse serum, 2 mmol/L
L‐glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin and
dissociated into single cells by several passages through a series of
syringe needles (23‐25G). Ganglia cells were centrifuged and sus-
pended in medium with the addition of normal growth factor
(100 ng/mL) and cytosine‐D‐arabinofuranoside free base (2.5 mmol/L).
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Neurons were then plated on glass coverslips coated with poly‐L‐
lysine (8.3 μmol/L) and laminin (5 μmol/L).
2.4 | Cellular recordings
Mobilization of intracellular calcium ([Ca2+]i) was measured in untras-
fected or transfected HEK293 cells, in IMR90 and in DRG neurons.
Cells on coated coverslips were loaded with 5 μmol/L Fura‐2 AM‐ester
(Alexis Biochemicals, Lausen, Switzerland) added to the extracellular
solution (37°C) containing the following (in mmol/L): 2 CaCl2, 5.4 KCl,
0.4 MgSO4, 135 NaCl, 10 D‐glucose, 10 HEPES and 0.1% bovine
serum albumin at pH 7.4. After 40 minutes loading, coverslips with
cells were washed and then transferred to a chamber on the stage of
an Olympus IX81 microscope for recording. Cells were excited alterna-
tively at 340 and 380 nm and recorded with a dynamic image analysis
system (XCellence Imaging software; Olympus srl, Milan, Italy). Results
were expressed as the percentage of increase in R340/380 over the
baseline (% Change in R340/380), and each effect was normalized to the
maximum effect induced by ionomycin (5 μmol/L).30 For whole‐cell
patch‐clamp recordings, coverslips with cells were transferred to a
recording chamber (1 mL volume), mounted on the platform of an
inverted microscope (Olympus CKX41) and superfused at a flow rate
of 2 mL/min with a standard extracellular solution at pH 7.4 (adjusted
with NaOH) containing (in mmol/L): 10 HEPES, 10 D‐glucose, 147
NaCl, 4 KCl, 1 MgCl2, and 2 CaCl2. Borosilicate glass electrodes (Har-
vard Apparatus, Holliston, MA, USA) were pulled with a Sutter Instru-
ments puller (model P‐87) to a final tip resistance of 4‐7 MΩ. Pipette
solution used for HEK293 cells contained (in mmol/L): 134 K‐gluco-
nate, 10 KCl, 11 EGTA, 10 HEPES (pH adjusted to 7.4 with KOH).
When recordings were performed on rat DRG neurons, the extracellu-
lar solution contained 5 mmol/L CaCl2, and pipette solution contained
(in mmol/L): 120 CsCl, 3 Mg2ATP, 10 BAPTA, 10 HEPES‐Na (pH
adjusted to 7.4 with CsOH). Data were acquired with an Axopatch
200B amplifier (Axon Instruments, CA, USA), stored and analysed with
a pClamp 9.2 software (Axon Instruments). All the experiments were
carried out at room temperature (20‐22°C). Currents were detected as
inward currents activated on cell superfusion with the various stimuli
in the voltage‐clamp mode (holding potential of −60 mV). Cell mem-
brane capacitance was calculated in each cell throughout the experi-
ment by integrating the capacitive currents elicited by a ±10 mV
voltage pulse. Peak currents were normalized to cell membrane capaci-
tance and expressed as mean of the current density (pA/pF) in aver-
aged results. Signals were sampled at 1 kHz and low‐pass filtered at
10 kHz.
Cells and neurons were challenged with safranal (0.1‐300 μmol/
L), picrocrocin (1‐300 μmol/L) and crocin (30‐200 μmol/L). Allyl‐iso-
thiocyanate (AITC, 1‐10 μmol/L) and GSK1016790A (0.05‐0.1 μmol/
L) were used to induce TRPA1 and a TRPV4 selective response
respectively. Capsaicin (0.1‐1 μmol/L) was used to induce a TRPV1
selective response and to identify capsaicin‐sensitive neurons. Buffer
solution containing dimethyl sulfoxide (DMSO, 1%) was used as
vehicle. The activating peptide for human proteinase‐activated
receptor 2 (hPAR2‐AP; 100 μmol/L) or KCl (40‐80 mmol/L) were
used to elicit a TRP‐independent cellular response. Some experi-
ments were performed in the presence of TRPA1, TRPV1 and
TRPV4 selective antagonists, HC‐030031 (50 μmol/L), capsazepine
(10 μmol/L) and HC‐067047 (30 μmol/L) respectively, or their vehi-
cles (0.5% or 0.1% or 0.3% DMSO respectively).
2.5 | Organ bath assay
Rat urinary bladder was excised from rat, and longitudinal strips
were suspended at a resting tension of 1 g in 10‐mL organ bath
bathed in aerated (95% O2 and 5% CO2) Krebs‐Henseleit solution
maintained at 37°C containing (in mmol/L): 119 NaCl, 25 NaHCO3,
1.2 KH2PO4, 1.5 MgSO4, 2.5 CaCl2, 4.7 KCl and 11 D‐glucose. After
40 minutes of equilibration, tissues were challenged twice with car-
bachol (CCh, 1 μmol/L), with a 45‐minute washing out period
between the two administrations. Motor activity was recorded on a
force transducer isometrically (Harvard Apparatus, Ltd, Kent, UK).
Tissues were challenged with safranal (10‐300 μmol/L), AITC
(100 μmol/L), GSK1016790A (10 μmol/L) and capsaicin (0.3 μmol/L)
or their vehicles. In some experiments, tissues were pre‐exposed to
HC‐030031 (50 μmol/L), capsazepine (10 μmol/L), HC‐067047
(30 μmol/L) or a combination of NK1 and NK2 receptor antagonists,
L‐733,060 and SR48968 respectively (both 1 μmol/L). Some prepara-
tions were desensitized by treatment with a high concentration of
capsaicin (10 μmol/L for 20 minutes, twice) or were exposed to
safranal (300 μmol/L for 20 minutes, twice) before the challenge with
other stimuli. Responses were expressed as percentage (%) of the
maximum contraction, induced by CCh (1 μmol/L).
2.6 | CGRP‐like immunoreactivity assay
For CGRP‐like immunoreactivity (CGRP‐LI) outflow, 0.4‐mm slices of
rat or mouse spinal cord were superfused with an aerated (95% O2
and 5% CO2) Krebs‐Henseleit solution modified with 0.1% bovine
serum albumin plus the angiotensin‐converting enzyme inhibitor,
captopril (1 μmol/L) and the neutral endopeptidase inhibitor, phos-
phoramidon (1 μmol/L) to minimize peptide degradation. Fractions
(4 mL) of superfusate were collected at 10‐minute intervals before,
during and after administration of the stimuli and then freeze‐dried,
reconstituted with assay buffer, and analysed for CGRP‐LI using a
commercial enzyme‐linked immunosorbent assay kit (Bertin Pharma,
Montigny le Bretonneux, France). Detection limits of the assays
were 5 pg/mL. Stimuli did not cross‐react with CGRP antiserum. Tis-
sues were stimulated with safranal (10‐300 μmol/L) or its vehicle (1%
DMSO). Some tissues were pre‐exposed to capsaicin (10 μmol/L,
30 minutes) or superfused with a calcium‐free buffer containing
EDTA (1 mmol/L). Some preparations were pre‐exposed to TRPA1
antagonist, HC‐030031 (50 μmol/L), capsazepine (10 μmol/L) or HC‐
067047 (30 μmol/L). Other tissues were pre‐exposed to safranal
(100 μmol/L, 30 minutes) and then, after a prolonged washing
(40 minutes), stimulated with AITC (50 μmol/L) capsaicin (0.1 μmol/L)
or GSK1016790A (10 μmol/L). Results were expressed as femto-
moles of peptide per gram of tissue.
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2.7 | Acute nociceptive response
The acute nociception was assessed in C57BL/6, Trpa1+/+ and
Trpa1−/−, Trpv1+/+ and Trpv1−/− or Trpv4+/+ and Trpv4−/− mice, after
intraplantar (i.pl.) injection (20 μL/paw) of safranal (0.2‐20 nmol),
AITC (10 nmol), capsaicin (0.2 nmol), GSK1016790A (2 nmol) or their
vehicle (7% and 0.5% DMSO). Immediately after injection, mice were
placed individually in plexiglas chambers and the amount of time
(seconds) spent licking and shaking the injected paw was recorded
for a 5‐minute time period, as previously described.31 Nociception
induced by safranal (20 nmol) was also evaluated 60 minutes after
intraperitoneal (i.p.) treatment with HC‐030031 (100 mg/kg) or
30 minutes after capsazepine (4 mg/kg) or HC‐067047 (10 mg/kg) or
their vehicle (all, 4% DMSO plus 4% tween 80 in isotonic saline,
0.9% NaCl). In another experimental setting, safranal (0.5‐1 mg/kg,
i.g.) was administered each day for 5 consecutive days.8 Each day,
60 minutes after safranal i.g. administration, AITC (10 nmol), cap-
saicin (0.2 nmol) or GSK1016790A (2 nmol) or their vehicles (0.5%
DMSO) were administered (20 μL, i.pl.) and acute nociceptive
response was recorded.
2.8 | Drugs and reagents
HC‐030031 [2‐(1,3‐dimethyl‐2,6‐dioxo‐1,2,3,6‐tetrahydro‐7H‐purin‐7‐
yl)‐N‐(4‐isopropylphenyl) acetamide] was synthesized as previously
described.32 If not otherwise indicated, all other reagents were
obtained from Sigma‐Aldrich (Milan, Italy).
2.9 | Statistical analysis
Statistical analysis was performed using the unpaired two‐tailed Stu-
dent's t test for comparisons between two groups and the one‐ or
two‐way ANOVA, followed by the post‐hoc Bonferroni's test for
comparisons of multiple groups (GraphPad Prism version 5.00, San
Diego, CA, USA). A P < 0.05 was considered statistically significant.
Data are reported as mean ± SEM.
3 | RESULTS
3.1 | Safranal and picrocrocin, but not crocin,
selectively activate the human TRPA1 channel
Safranal and picrocrocin evoked a concentration‐dependent calcium
response in hTRPA1‐HEK293 (EC50s 17 ± 0.3 μmol/L and 56 ± 0.3
μmol/L respectively), but not in naïve HEK293 cells (Figure 1B). The
selective TRPA1 antagonist HC‐030031 attenuated the response
evoked by safranal and picrocrocin and AITC (Figure 1B). Crocin, the
third main constituent of saffron was not investigated in this test
because of its intense yellow colour which interferes with the
recording system. Thus, the ability of crocin to target TRPA1 was
analysed by whole‐cell patch‐clamp electrophysiology. Crocin did not
evoke any measurable inward current in hTRPA1‐HEK293, compared
to its vehicle (Figure 1C).
Further investigation was limited to safranal, the most potent of the
three compounds. The non‐electrophilic agonist, menthol, evoked a
robust calcium response in 3C/K‐Q hTRPA1‐HEK293 cells, which
express a mutant form of the TRPA1 receptor, lacking three key cys-
teine (C619, C639, C663) and one lysine (K708) residues, which are
required for channel activation by electrophilic agonists23,33 (Figure 1D).
However, safranal failed to induce any calcium response in 3C/K‐Q
hTRPA1‐HEK293 cells (Figure 1D). Finally, in IMR90 cells, which consti-
tutively express the native human TRPA1 receptor,34 safranal and picro-
crocin evoked concentration‐dependent calcium responses (EC50s
9 ± 0.2 μmol/L and 44 ± 0.4 μmol/L respectively) that were attenuated
by HC‐030031, alike the response evoked by AITC (Figure 1E).
Similar results were obtained in whole‐cell patch‐clamp recording
experiments. Safranal elicited concentration‐dependent inward cur-
rents in hTRPA1‐HEK293 cells, an effect that was attenuated by
HC‐030031 and was absent in untransfected HEK293 cells (Fig-
ure S1A). Either safranal or picrocrocin failed to evoke calcium
responses or inward currents (safranal) in HEK293 cells transfected
with the human TRPV1 (hTRPV1‐HEK293) or TRPV4 (hTRPV4‐
HEK293) that, however, were efficiently stimulated by their selective
agonists, capsaicin and GSK1016790A respectively (Figure S1B‐E). In
all experiments, calcium responses elicited by hPAR2‐AP and ion cur-
rents evoked by KCl were not affected by HC‐030031, indicating
selectivity (Figure 1B,E and Figure S1A).
3.2 | Safranal selectively excites TRPA1 in rodent
sensory neurons
Exposure to safranal of cultured rat DRG neurons evoked a concen-
tration‐dependent calcium response in a subset of cells, identified as
nociceptors by their ability to respond to KCl, capsaicin and AITC31
(Figure 2A). In rat DRG neurons maximum calcium responses to
safranal or AITC were 35.8% ± 8.5% and 56.0% ± 6.0% of ionomycin
(n = 25, P < 0.01) respectively, and EC50s were 38 ± 0.03 μmol/L
and 5 ± 0.3 μmol/L respectively. Calcium responses were attenuated
by HC‐030031, and unaffected by the respective TRPV1 and TRPV4
selective antagonists, capsazepine and HC‐067047 (Figure 2A).
Safranal or AITC elicited inward currents in rat DRG neurons, that
were blocked by HC‐030031 (Figure 2B), which, however, did not
affect currents evoked by capsaicin, indicating selectivity (Figure 2A,
B). Safranal and AITC produced calcium responses in DRG neurons
isolated from Trpa1+/+ mice, but not in neurons isolated from
Trpa1−/− mice (Figure 2C), while the response to capsaicin was
unchanged in both mice strains.
3.3 | Safranal causes neuropeptides release and
acute pain via TRPA1 activation in nociceptors
There is evidence that TRPA1 is localized in peptidergic primary sen-
sory neurons.35,36 Central and peripheral endings of primary sensory
neurons are widely expressed in most tissues and organs, including
rat urinary bladder and rat or mouse spinal cord, where upon stimu-
lation they release proinflammatory neuropeptides, such as CGRP
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and SP. SP released upon stimulation of TRPV1 or TRPA1 results in
a contractile response of isolated strips of rat urinary bladder that is
mediated by activation of the NK1 and NK2 receptors for SP in
bladder smooth muscle cells.37
Safranal caused a concentration‐dependent contractile response
of isolated strips of rat urinary bladder with a slightly lower potency
than AITC (EC50s were 76 ± 0.07 μmol/L and 56 ± 0.02 μmol/L
respectively) (Figure 3A). Efficacy of safranal was also lower than
F IGURE 1 Safranal (SFR) and picrocrocin (PICR) selectively target the human TRPA1 channel. A, Chemical structures of SFR, PICR and
crocin (CRO). B, Concentration response curves of the calcium mobilization evoked by SFR and PICR in hTRPA1 HEK293 cells. Representative
traces and pooled data of calcium response evoked by SFR, PICR and AITC in hTRPA1 HEK293 pre‐exposed to HC‐030031 (HC03, 30 μmol/L)
or its vehicle (‐) and in naïve HEK293 cells. C, Representative traces and pooled data of whole‐cell patch‐clamp inward currents evoked by
CRO and AITC (100 μmol/L) in hTRPA1 HEK293. D, Pooled data of calcium responses evoked by SFR and menthol in wild‐type (wt) and
mutant (3C/K‐Q) hTRPA1 HEK293 transfected cells. E, Concentration response curves of the calcium mobilization evoked by SFR and PICR in
IMR90 cells. Representative traces and pooled data of calcium responses evoked by SFR, PICR and AITC pre‐exposed HC03 (30 μmol/L) or its
vehicle (‐) in IMR90 cells. HC03 does not affect the response evoked by the hPAR2‐AP (100 μmol/L). Veh is the vehicle of SFR, dash (‐)
indicates the vehicle of HC03. Data are mean ± SEM of n > 20 cells from 4 to 6 independent experiments (B, D, E) and n > 3 cells from 3 to
5 independent experiments (C). *P < 0.05 vs veh, §P < 0.05 vs SFR, PICR or AITC; one‐way ANOVA with Bonferroni post‐hoc correction
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that of AITC (maximum response, 15.5% ± 3.0% of carbachol, n = 6,
and 35.1% ± 6.2% of carbachol respectively, n = 6, P < 0.05) (Fig-
ure 3A). The response of safranal was attenuated by pre‐exposure to
a combination of NK1 and NK2 receptor antagonists (L‐733,060 and
SR48968 respectively), by pre‐exposure to a high concentration of
capsaicin able to desensitize the nociceptors and by pre‐exposure to
the TRPA1 selective antagonist, HC‐030031, while it was unaffected
by pre‐exposure to capsazepine (TRPV1 antagonist) and HC‐067047
(TRPV4 antagonist) (Figure 3A). This finding supports the hypothesis
that safranal behaves as a partial agonist at the TRPA1 channel.
Safranal elicited a concentration‐dependent increase in CGRP‐LI
outflow from rat spinal cord slices which was absent in a calcium‐
free medium or in tissues pre‐exposed to a desensitizing concentra-
tion of capsaicin and in the presence of HC‐030031 (Figure 3B).
Safranal‐evoked CGRP release was unaffected by capsazepine or
HC‐067047 (Figure 3B). Exposure to safranal increased CGRP out-
flow from dorsal spinal cord slices obtained from Trpa1+/+ mice, but
not from tissues taken from Trpa1−/− mice (Figure 3C). Thus, safranal
elicits CGRP release from a subset of TRPV1‐positive neurons via a
neurosecretory process, mediated by TRPA1.
F IGURE 2 Safranal (SFR) selectively activates TRPA1 in rodent primary sensory neurons. A, Concentration response curves of the calcium
mobilization evoked by SFR and AITC in rat DRG (rDRG) neurons. Representative traces and pooled data of calcium response evoked by SFR,
AITC and capsaicin (CPS) in rDRG neurons pre‐exposed to HC‐030031 (HC03, 50 μmol/L), capsazepine (CPZ; 10 μmol/L), HC‐067047 (HC06;
30 μmol/L) or their vehicles (‐). B, Representative traces and pooled data of whole‐cell patch‐clamp inward currents evoked by SFR, AITC and
CPS in rDRG neurons. HC03 does not affect the responses evoked by CPS. C, Representative traces and pooled data of the calcium responses
evoked by SFR or AITC in mouse DRG (mDRG) neurons from Trpa1+/+ and Trpa1−/− mice. Veh is the vehicle of SFR. Dash (‐) indicates vehicles
of the different treatments. Data are mean ± SEM of n > 20 cells from 4 to 6 independent experiments (A, C) and n > 3 cells from 3 to 5
independent experiments (B). *P < 0.05 vs veh; §P < 0.05 vs SFR or AITC; one‐way ANOVA with Bonferroni post‐hoc correction
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These ex vivo findings were replicated in an in vivo setting.
Injection of safranal (0.2‐20 nmol) into the mouse paw (20 μL, i.pl.)
evoked a dose‐dependent acute nociceptive response (Figure 3D).
The response evoked by the highest dose (20 nmol) of safranal was
attenuated by pretreatment with systemic administration HC‐
030031 (100 mg/kg, i.p.) and was absent in Trpa1−/− mice (Fig-
ure 3E,F). Selectivity of safranal action for TRPA1 was strengthened
by the observation that the nociceptive response evoked by i.pl.
safranal (20 nmol) in Trpv1+/+ and Trpv4+/+ was maintained in
Trpv1−/− and Trpv4−/− mice (Figure 3G,H). Similarly, the nociceptive
response to safranal was unaffected by pretreatment with TRPV1
and TRPV4 antagonists (capsazepine and HC‐067047 respectively)
(Figure 3E).
3.4 | In vitro and in vivo exposure to safranal
attenuated TRPA1‐mediated responses
In hTRPA1‐HEK293 transfected cells, inward currents evoked by
AITC underwent a concentration‐dependent attenuation after pre‐
exposure to increasing concentrations of safranal (Figure 4A),
whereas KCl‐evoked currents were not affected (Figure 4A). In
cultured rat DRG neurons, pre‐exposure to safranal reduced inward
currents evoked by AITC, but not currents evoked by capsaicin, sug-
gesting that safranal promotes selective TRPA1 desensitization (Fig-
ure 4B). Specific desensitization of TRPA1 was also observed in
organ bath experiments. Pre‐exposure to safranal reduced contractile
responses of rat urinary bladder strips evoked by safranal and AITC,
but not those evoked by capsaicin, GSK1016790A or carbachol (Fig-
ure 4C). Finally, pre‐exposure to safranal was able to markedly
reduce CGRP release from rat spinal cord evoked by AITC, without
affecting the release evoked by capsaicin or GSK1016790A
(Figure 4D).
To test whether pre‐exposure to safranal could desensitize
TRPA1‐mediated responses in vivo, safranal was administered by the
intragastric route (i.g.) at two different doses (0.5‐1 mg/kg). One sin-
gle i.g. administration of either doses (day 1) did not affect the ability
of local (i.pl.) AITC, capsaicin or GSK1016790A to evoke acute noci-
ceptive responses (Figure 5A‐C). After administration of the two
doses of safranal for 3 consecutive days the nociceptive responses
evoked by i.pl. AITC were slightly reduced, but not those evoked by
capsaicin and GSK1016790A (Figure 5A‐C). After administration of
the two doses of safranal for 5 consecutive days the nociceptive
F IGURE 3 Safranal (SFR) activating TRPA1 in nociceptors causes neuropeptides release and pain. A, Concentration response curves of the
contractile response induced by SFR and AITC in rat urinary bladder. Pooled data of the contractile response evoked by SFR in rat urinary
bladder pre‐exposed to a combination of NK1/NK2 receptor antagonists (NK1/2 RA; L‐733,060 and SR48968, both 1 μmol/L), to a high
concentration of capsaicin (CPS des; 10 μmol/L), HC‐030031 (HC03, 50 μmol/L), capsazepine (CPZ; 10 μmol/L), HC‐067047 (HC06; 30 μmol/L)
or their vehicles (‐). B, Pooled data of CGRP release evoked by SFR from rat dorsal spinal cord after calcium removal (Ca2+ free), or after
capsaicin desensitization (CPS des; 10 μmol/L), or exposed to HC03 (50 μmol/L), CPZ (10 μmol/L) or HC06 (30 μmol/L). (C) CGRP release
evoked by SFR from dorsal spinal cord from Trpa1+/+ and Trpa1−/− mice. D, Dose‐dependent acute nociceptive response evoked by
intraplantar (i.pl.) injection (20 μL) of SFR in C57BL/6 mice. E, Pooled data of the acute nociceptive response evoked by SFR (20 nmol, i.pl.)
after intraperitoneal (i.p.) HC03 (100 mg/kg), CPZ (4 mg/kg), HC06 (10 mg/kg) or their vehicles (‐, 4% DMSO, 4% tween 80 in 0.9% NaCl). F‐H,
Acute nociceptive response evoked by SFR (20 nmol, i.pl.) in Trpa1+/+ and Trpa1−/−, Trpv1+/+ and Trpv1−/−, and Trpv4+/+ and Trpv4−/− mice.
Veh is the vehicle of SFR. Dash (‐) indicates vehicles of treatments. Data are mean ± SEM of 4‐6 independent experiments (A‐C) and n = 6
mice per group (D‐H). *P < 0.05 vs Veh; §P < 0.05 vs SFR; one‐way ANOVA with Bonferroni post‐hoc correction
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responses evoked by i.pl. AITC were markedly attenuated, the effect
of the highest dose of safranal being more pronounced (Figure 5A).
Nociceptive responses evoked by both capsaicin and GSK1016790A
were unaffected (Figure 5B,C).
4 | DISCUSSION
Present results show that two of the three main constituents of saf-
fron, safranal and its precursor, picrocrocin, target the mouse, rat and
human (native and recombinant) TRPA1, whereas the third con-
stituent, crocin, was completely inactive. The lower potency of picro-
crocin compared to safranal may depend on various factors. The
presence of two β substituents on the double bond and chemical
instability as compared to safranal38 could explain the lower reactivity
of picrocrocin. The failure to stimulate TRPV1 or TRPV4 channels
indicates that nociceptor activation by safranal is selectively mediated
by TRPA1. Interestingly, safranal failed to evoke any calcium response
in HEK293 cells transfected with mutant TRPA1 (3C/K‐Q) channel,
indicating that, similarly to other electrophilic and reactive ago-
nists,23,33 channel activation by the saffron constituent is mediated by
specific cysteine/lysine residues. Both potency and efficacy of the cal-
cium response evoked by safranal in cultured rat DRG neurons were
lower than that of AITC. In particular, the lower efficacy supports the
hypothesis that safranal may act as a partial TRPA1 agonist.
Peptidergic sensory neurons expressing TRPA1 exert a dual
afferent and efferent role, because upon stimulation they can both
signal pain to the brain and release from their peripheral terminals
the neuropeptides SP and CGRP, which mediate neurogenic inflam-
matory responses.13,39 One of these responses is the SP‐mediated
contraction of rat urinary bladder smooth muscle,40 which can be
also produced by TRPA1 activation in intramural sensory nerve ter-
minals.37 Here, we found that safranal produced a contraction mech-
anistically similar to that induced by AITC, because it was abrogated
after exposure to a high, desensitizing, concentration of capsaicin, in
the presence of a TRPA1 selective antagonist and in the presence of
a combination of NK1 and NK2 receptor antagonists. Notably, the
efficacy of safranal to target TRPA1 in the urinary bladder was lower
than that of AITC, further supporting a possible partial agonism of
the compound.
Results obtained in vitro were recapitulated in an in vivo set-
ting, where the proalgesic action of safranal was mediated exclu-
sively by TRPA1. Intraplantar injection of safranal elicited a
concentration‐dependent acute nociceptive response that was
TRPA1‐dependent, being selectively attenuated by TRPA1 antago-
nism and gene deletion. However, there is also indication that saf-
fron has beneficial effect in certain pain conditions.3,41 Furthermore,
safranal has been reported to attenuate pain‐like responses in animal
models of inflammatory and neuropathic pain.8–10 In particular, safra-
nal attenuated mechanical allodynia and thermal hyperalgesia in a
chronic constriction injury model,10 suppressed the second phase of
the orofacial pain induced by formalin42 and the late phase of the
carrageenan‐induced paw oedema.8 The apparent contradiction
between these findings and the ability of safranal to excite the
F IGURE 4 Safranal (SFR) causes
desensitization. A, Representative traces
and pooled data of whole‐cell patch‐clamp
inward currents of the concentration
dependant desensitization induced by SFR
in response to AITC and KCl in hTRPA1
HEK293. B, Representative traces and
pooled data of whole‐cell patch‐clamp
inward currents of the desensitization
induced by SFR in response to AITC and
capsaicin (CPS) in rat DRG (rDRG) neurons.
C, Pooled data of the desensitization
induced by SFR in the contractile response
evoked by SFR, AITC, CPS, GSK and
carbachol (CCh). D, Pooled data of the
desensitization induced by SFR in CGRP‐LI
release from rat spinal cord evoked by
AITC, CPS and GSK. Veh is the vehicle of
SFR. Data are mean ± SEM of n > 3 cells
from 3‐5 independent experiments (A, B)
and 4‐6 independent experiments (C, D).
§P < 0.05 vs AITC, SFR; one‐way ANOVA
followed by Bonferroni test. #P < 0.05 vs
AITC and SFR, Student's t test
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proalgesic TRPA1 may be explained considering that pre‐exposure to
safranal of cultured DRG neurons selectively attenuated AITC‐
evoked responses, without affecting TRPA1‐independent responses.
In vitro results were recapitulated by in vivo experiments, where
repeated administration (5 days) of i.g. safranal reduced the acute
nociceptive responses evoked by local AITC, leaving unaffected the
nociceptive responses evoked by TRPV1 or TRPV4 stimulation. Thus,
safranal attenuates the afferent function of nociceptors apparently
by promoting a process of homologous desensitization of the TRPA1
channel, which might contribute to the antinociceptive properties of
saffron. More recently, it has been demonstrated that TRPA1 is
expressed by Schwann cells, where it can amplify and sustain macro-
phage‐dependent neuropathic pain.19 Thus, it is possible that
safranal exerts its partial agonist and desensitizing activities at the
Schwann cell TRPA1, contributing in this manner to reduce neuro-
pathic pain.
Clinical investigations with saffron has reported headache as a
possible adverse reaction.4 In contrast with this observation, saffron
has been used by Indian traditional medicine to treat headaches.5
TRPA1 is preferentially expressed by peptidergic sensory neurons,
and upon its activation evokes the simultaneous release of the proin-
flammatory and proalgesic neuropeptides, SP and CGRP.21,43 CGRP
is now considered a major contributor of migraine pain as small
molecule CGRP receptor antagonists and monoclonal antibodies
against CGRP or its receptor have marked beneficial effects in
migraine.13,15 The observation that in strips rat urinary bladder and
in rat dorsal spinal cord slices pre‐exposure to safranal reduced
AITC‐evoked SP‐mediated contractile responses and CGRP release
respectively, without affecting TRPA1‐independent responses further
suggests that safranal attenuates the efferent and pro‐migraine func-
tion of peptidergic nociceptors.
We previously showed that upon in vitro or in vivo exposure
to other herbal preparations, such as isopetasin, contained in
butterbur [Petasites hybridus (L.) Gaertn.],29 and parthenolide, a
major constituent of Tanacetum parthenium,30 TRPA1‐expressing
trigeminal neurons undergo concentration‐ or dose‐dependent
desensitization. However, while isopetasin and parthenolide evoked
non‐selective desensitization of peptidergic nociceptors as they also
attenuated responses mediated by TRPV1 and TRPV4 activa-
tion,29,30 safranal seems to selectively reduce responses elicited by
TRPA1 agonism. The mechanism of the selective activity of safranal
is unknown. Different pharmacokinetic properties or distinct activa-
tion of intracellular signalling mechanisms may be the causes of the
diverse ability of the three herbal derivatives to desensitize the
channel, and these deserve further investigation. Nevertheless,
safranal, one major constituent of saffron extract, targets TRPA1
with a lower potency than full agonists and attenuates responses
mediated by TRPA1 activation by other stimuli. The dual action of
safranal on TRPA1 might contribute to the reported either detri-
mental or beneficial actions of the compound in animal models of
pain and of saffron in humans.
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